Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.65 |
| ▸ | KIT | P10721 | 17/20 | 0.61 |
| ▸ | ABL1 | P00519 | 1/20 | 0.55 |
| ▸ | DDR1 | Q08345 | 13/20 | 0.53 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29602539 | 1.00 | CSF1R (0.65) | CSF1RKITABL1DDR1DDR2 | |
| SCHEMBL22833530 | 0.86 | CSF1R (0.61) | CSF1RKITABL1DDR1DDR2 | |
| SCHEMBL22833839 | 0.85 | CSF1R (0.65) | CSF1RKITABL1DDR1DDR2 | |
| SCHEMBL29506321 | 0.85 | CSF1R (0.65) | CSF1RKITABL1DDR1DDR2 | |
| SCHEMBL22833926 | 0.84 | CSF1R (0.64) | CSF1RKITABL1DDR1DDR2 | |
| SCHEMBL22833516 | 0.84 | CSF1R (0.61) | CSF1RKITABL1DDR1DDR2 | |
| SCHEMBL24925721 | 0.83 | CSF1R (0.62) | CSF1RKITABL1DDR1DDR2 | |
| SCHEMBL22833536 | 0.83 | CSF1R (0.62) | CSF1RKITABL1DDR1DDR2 | |
| SCHEMBL29506239 | 0.83 | CSF1R (0.62) | CSF1RKITABL1DDR1DDR2 | |
| SCHEMBL22833523 | 0.83 | CSF1R (0.59) | CSF1RKITABL1DDR1DDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230014226-A1 | NEW COMPOUNDS AND METHODS | BENEVOLENTAI BIO LIMITED (GB) | 2023-01-19 | — | — | US | claimed |
| EP-3986559-A1 | NEW COMPOUNDS AND METHODS | BenevolentAI Bio Limited (GB) | 2022-04-27 | — | — | EP | claimed |
| CN-114340734-A | Novel compounds and methods | 博善人工智能生物科技有限公司 | 2022-04-12 | — | — | CN | claimed |
| WO-2020260871-A1 | NEW COMPOUNDS AND METHODS | BENEVOLENTAI BIO LIMITED (GB) | 2020-12-30 | — | — | WO | claimed |
| US-20230014226-A1 | NEW COMPOUNDS AND METHODS | BENEVOLENTAI BIO LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| US-20230014226-A1 | NEW COMPOUNDS AND METHODS | BENEVOLENTAI BIO LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| EP-3986559-A1 | NEW COMPOUNDS AND METHODS | BenevolentAI Bio Limited (GB) | 2022-04-27 | — | — | EP | disclosed |
| CN-114340734-A | Novel compounds and methods | 博善人工智能生物科技有限公司 | 2022-04-12 | — | — | CN | disclosed |
| WO-2020260871-A1 | NEW COMPOUNDS AND METHODS | BENEVOLENTAI BIO LIMITED (GB) | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014226-A1 | NEW COMPOUNDS AND METHODS | ABL2, ABL1, ALK | CSF1R 4175/4885KIT 457/4885ABL1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.